NeuroOne Medical Technologies Corporation: 10-Q filed 2023-05-12
What NeuroOne Medical Technologies Corporation reported in its quarterly report filed 2023-05-12 (fiscal Q2 2023): 41 published measures, 115 facts as tagged in accession 0001213900-23-039030.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-05-12
- Fiscal period
- fiscal Q2 2023
- Accession
- 0001213900-23-039030 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuroOne Medical Technologies Corporation filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 7,205,106 | USD | |
| At 2022-09-30 | 12,822,609 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,672,282 | USD | |
| At 2022-09-30 | 3,218,245 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 5,532,824 | USD | |
| At 2022-12-31 | 8,171,776 | USD | |
| At 2022-09-30 | 9,604,364 | USD | |
| At 2022-03-31 | 13,122,449 | USD | |
| At 2021-12-31 | 15,947,800 | USD | |
| At 2021-09-30 | 6,553,901 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 3,602,163 | USD | |
| At 2022-09-30 | 8,160,329 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -3,522,828 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -5,255,597 | USD | 182 |
| 2022-10-01 to 2022-12-31 | -1,732,769 | USD | 92 |
| 2022-01-01 to 2022-03-31 | -3,058,067 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -5,865,542 | USD | 182 |
| 2021-10-01 to 2021-12-31 | -2,807,475 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -7,043,789 | USD | 182 |
| 2021-10-01 to 2022-03-31 | -5,900,727 | USD | 182 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 187,206 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 154,810 | USD | 182 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 466,176 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 580,755 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 36,584 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 70,332 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 646,248 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 12,023,282 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 1,839,375 | USD | 182 |
| 2021-10-01 to 2022-03-31 | -154,810 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -56,082,409 | USD | |
| At 2022-09-30 | -50,826,812 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 16,414,795 | shares | 90 |
| 2022-10-01 to 2023-03-31 | 16,321,891 | shares | 182 |
| 2022-01-01 to 2022-03-31 | 16,189,867 | shares | 90 |
| 2021-10-01 to 2022-03-31 | 15,794,880 | shares | 182 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 16,414,795 | shares | 90 |
| 2022-10-01 to 2023-03-31 | 16,321,891 | shares | 182 |
| 2022-01-01 to 2022-03-31 | 16,189,867 | shares | 90 |
| 2021-10-01 to 2022-03-31 | 15,794,880 | shares | 182 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.21 | USD/shares | 90 |
| 2022-10-01 to 2023-03-31 | -0.32 | USD/shares | 182 |
| 2022-01-01 to 2022-03-31 | -0.19 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | -0.37 | USD/shares | 182 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.21 | USD/shares | 90 |
| 2022-10-01 to 2023-03-31 | -0.32 | USD/shares | 182 |
| 2022-01-01 to 2022-03-31 | -0.19 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | -0.37 | USD/shares | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 522,810 | USD | |
| At 2022-09-30 | 353,599 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -3,495,919 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -5,280,271 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -3,059,810 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -5,869,135 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 6,356,557 | USD | |
| At 2022-09-30 | 12,175,763 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,550,386 | USD | |
| At 2022-09-30 | 3,098,689 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 953,446 | USD | |
| At 2022-09-30 | 927,662 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 213,952 | USD | |
| At 2022-09-30 | 33,237 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 3,527,422 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 6,754,655 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 3,023,587 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 5,826,190 | USD | 182 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 1,174,307 | USD | |
| At 2022-09-30 | 704,538 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 31,503 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 19,196 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -36,223 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -49,319 | USD | 182 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 434,673 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 561,559 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 72,807 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 119,651 | USD | 182 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 1,821,108 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 3,484,845 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 1,818,207 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 3,560,348 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 1,706,314 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 3,269,810 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 1,205,380 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 2,265,842 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 16,887,738 | shares | |
| At 2022-09-30 | 16,216,540 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 61,598,345 | USD | |
| At 2022-09-30 | 60,414,959 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 225,005 | USD | |
| At 2022-09-30 | 181,355 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 777,808 | USD | |
| At 2022-09-30 | 539,956 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 254,998 | USD | |
| At 2022-09-30 | 186,357 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 100,734 | USD | |
| At 2022-09-30 | 111,892 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 596,940 | USD | |
| At 2022-09-30 | 715,839 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -3,522,828 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -5,255,597 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -3,058,067 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -5,865,542 | USD | 182 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 38,331 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 68,641 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 22,952 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 42,534 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 79,799 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 53,692 | USD | 182 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 11,158 | USD | 182 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 180,715 | USD | 182 |
| 2021-10-01 to 2022-03-31 | -11,752 | USD | 182 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | 469,769 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 123,616 | USD | 182 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -24,862 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 33,800 | USD | 182 |
Inspect the source
- Entity
- NeuroOne Medical Technologies Corporation / CIK 0001500198
- Captured
- 2026-09-20T09:11:29.314Z
- SEC response SHA-256
dec08ad6d59f8d84b3a6db4a6ff83df3a276b794fed82089495b0788055433dd
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001500198.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))